SOLICITATION NOTICE
A -- Notice of Intent to Award a Sole Source Contract Modification
- Notice Date
- 7/13/2017
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services - Rockville, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001, United States
- ZIP Code
- 20857-0001
- Solicitation Number
- FDA-SS-1185720
- Archive Date
- 8/5/2017
- Point of Contact
- Lisa K. Yaw, Phone: 2404024018
- E-Mail Address
-
lisa.yaw@fda.hhs.gov
(lisa.yaw@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- The Food and Drug Administration intends to modify contract HHSF223201610018C, "Sequelae and Immunopathology of Ebola Virus Infections" in the amount of $375,000. The contract modification will be awarded to: Leland Stanford Junior University 450 Serra Hall Stanford, CA 94305 In accordance with FAR 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements. Stanford is currently conducting the study on Sequelae and Immunopathology of Ebola Virus Infections under FDA contract HHSF223201610018C. Under this contract, Stanford has developed unique analytic tools vital to the completion of this study, and therefore they are the only ones that can collect the additional data required by FDA. FDA subject matter experts identified an opportunity to include tissue types infected with Zika Virus in addition to the Ebola samples that are already part of the study. The study protocols have been developed and are in place to analyze Ebola samples. As the Zika Virus tissue testing will utilize the same equipment and expertise previously developed by Stanford, it is the only organization that is able to add Zika samples to this ongoing study. No other organization can provide this service to study the effects of the Zika Virus in this manner. FDA/OCET requires the expansion of the list of Non-human primate tissues currently under study to include 38 tissue types infected with Zika Virus (ZIKV). Objectives of the modified study are to complete the original SOW for the Ebola virus with the addition of the Zika Virus samples. The addition of 38 tissue types obtained for Zika-infected NHPs will be analyzed via MIBI and/or CODEX for study of disease tropism in infected samples. Stanford will analyze the additional samples to provide the FDA with data regarding the lasting effects of Zika Virus in addition to the Ebola Virus. The NAICS code for this action is 541712. This procurement is made under the authority of FAR 6.302- Only one responsible source and no other supplies or services will satisfy agency requirements. This is a notice of intent to issue an award on a sole source basis. This notice of intent is not a solicitation for competitive proposals. Any other firms desiring consideration must fully identify their interest and capability to provide this item to: Lisa Yaw Contracts Specialist Lisa.Yaw@fda.hhs.gov 240-402-4018 A determination by the government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. The projected award date is on or about July 21, 2017.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/FDA-SS-1185720/listing.html)
- Place of Performance
- Address: Stanford, California, 94305, United States
- Zip Code: 94305
- Zip Code: 94305
- Record
- SN04579273-W 20170715/170714000208-5103c98b6baedf4e7ccafe286f3e87b1 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |